SentiBioLogo.jpg
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program
05 janv. 2024 16h05 HE | Senti Biosciences, Inc.
– Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024...
SentiBioLogo.jpg
Senti Bio to Participate in Upcoming Conferences
26 sept. 2023 16h05 HE | Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies...
SentiBioLogo.jpg
Senti Bio to Participate in Upcoming Investor Conferences
05 sept. 2023 08h30 HE | Senti Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company developing a new generation of cell and gene therapies...